论文部分内容阅读
目的 观察伊贝沙坦治疗轻、中度原发性高血压病人的疗效及耐受性。方法 用伊贝沙坦治疗 186例轻、中度原发性高压病人 12周。结果 病人于服药第 2、4、6、8、12周时 ,显效率分别为 4 0 3%、4 7 3%、5 4 4 %、6 3 2 %、71 1% ;有效率分别为 12 3%、17 3%、2 0 9%、2 2 6 %、2 3 3%。总有效率分别为 5 2 6 % ,6 4 6 % ,75 3% ,85 8% ,94 4 %。单用伊贝沙坦治疗 ,收缩压、舒张压、平均血压于第2周便开始明显下降 ,此后 ,随治疗时间的延长 ,血压不断下降 ,降压治疗的最大效应发生在第 12周。整个治疗过程无严重副作用发生。结论 伊贝沙坦治疗轻、中度原发性高血压病人安全有效 ,其疗效在不同年龄及不同体重指数的病人之间无明显差别。
Objective To observe the efficacy and tolerability of irbesartan in patients with mild to moderate essential hypertension. Methods 186 patients with mild to moderate essential hypertension were treated with irbesartan for 12 weeks. Results At the 2nd, 4th, 6th, 8th and 12th week, the effective rates were 40.3%, 47.3%, 54.4%, 63.2% and 71.1% respectively. The effective rates were 12 3%, 17 3%, 20 9%, 22 26%, 23 3%. The total effective rates were 52.6%, 64.6%, 75.3%, 85.8% and 94.4% respectively. With irbesartan alone, systolic blood pressure, diastolic blood pressure and mean blood pressure began to decrease significantly at the second week. From then on, the blood pressure decreased with the prolongation of treatment time. The maximum effect of antihypertensive treatment occurred at the 12th week. The entire course of treatment without serious side effects. Conclusion Irbesartan in the treatment of mild to moderate essential hypertension patients is safe and effective, the efficacy of different ages and different body mass index between patients no significant difference.